Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX01 versus MabThera in first-line low tumour burden follicular lymphoma
2020-000736-21Phase 3Terminated
- Sponsor
- Henlius
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) and mature B-cell lymphoma (2 arms), sponsored by Henlius. Primary endpoint: Overall response rate up to Week 28. Started Apr 2020; status: terminated.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2020-000736-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000736-21.